Aptahem ROE

Mitä Aptahem tekee? Aptahem AB is a biotechnology company based in Malmö, Sweden, operating within the healthcare sector. The company focuses on developing drug candidates aimed at treating and preventing diseases caused by blood vessel blockages due to blood clots, including conditions such as deep vein thrombosis, stroke, and heart failure. Aptahem AB went public through an IPO on April 17, 2015, and is listed under the ticker APTA.SL with ISIN SE0022447173. The company's headquarters are located in Malmö, a city in the Skåne region of Sweden. While the source material mentions a founding year of 2014, this detail is not confirmed by the provided facts, so it is omitted. Aptahem AB's website, aptahem.com, serves as the primary online resource for information about the company's activities and developments. The company operates in the biotechnology industry, specializing in therapeutic solutions for cardiovascular and related conditions. As a publicly traded entity, Aptahem AB is subject to the regulatory requirements of the Swedish financial market. The firm's strategic focus lies in addressing unmet medical needs through innovative drug development, targeting conditions that significantly impact patient outcomes and healthcare systems. The company's operations are centered in Malmö, reflecting its commitment to contributing to the biotechnology ecosystem in southern Sweden. Aptahem on yksi Eurpooliin suosituimmista yhtiöistä.